Drug Delivery System

AMELIA ISLAND, Fla. — In this video from Cataract Surgery: Telling It Like It Is, Robert J. Weinstock, MD, discusses a new technique he and Robert H. Osher, MD, developed to place Dexycu in the capsular bag during cataract surgery.

AMELIA ISLAND, Fla. — A new intraoperative ketorolac delivery device has the potential to disrupt NSAID delivery in cataract surgery, according to a presenter here.

WAILEA, Hawaii — In this video at Hawaiian Eye 2021, Savak Teymoorian, MD, MBA, discusses how the Durysta bimatoprost implant 10 µg from Allergan obviates the need for patients with glaucoma to instill drops.

Clinical trials have clearly laid out treatment protocols, usually with monthly treatment intervals, and the subjects tend to be compliant and motivated for the study visits. In the real world, life gets in the way.

Vision outcomes using a port delivery system proved equivalent to ranibizumab injections and showed a positive benefit profile, according to data presented at the virtual American Academy of Ophthalmology annual meeting.

Between poor patient adherence and the inherent IOP peaks and troughs associated with eye drop-managed glaucoma, sustained-release medications are greatly needed, a presenter at the virtual OSN New York meeting said.

There are long-term concerns about gene therapy for a number of reasons.

Durable treatment options that ensure consistent treatment outcomes and reduce the burden of multiple injections are an unmet need for neovascular age-related macular degeneration and other retinal vascular diseases treated with anti-VEGFs.

The most common drugs injected into the vitreous to treat posterior segment disease are steroids and anti-VEGF medication. To keep it simple, I will use trade names when available.

In this video from the virtual American Society of Retina Specialists meeting, Daniel Kiernan, MD, FACS, discusses his study of dexamethasone intracameral drug suspension (Dexycu, EyePoint) for inflammation following vitreoretinal surgery.